Author:
Lehrieder Dominik,Zapantis Nikolaos,Pham Mirko,Schuhmann Michael Klaus,Haarmann Axel
Abstract
BackgroundNeuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively.Case presentationWe report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.ConclusionTreatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.
Subject
Neurology (clinical),Neurology
Reference15 articles.
1. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome;Jarius;J Neuroinflammation,2016
2. Neuromyelitis Spectrum disorders;Weinshenker;Mayo Clin Proc,2017
3. Eculizumab in Aquaporin-4-positive Neuromyelitis Optica Spectrum disorder;Pittock;N Engl J Med,2019
4. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial;Traboulsee;Lancet Neurol,2020
5. Trial of Satralizumab in Neuromyelitis Optica Spectrum disorder;Yamamura;N Engl J Med,2019